Raloxifene hydrochloride
-
Molecular Structure
Detailed Description
Alias: RALOXIFENE HCL; ly156758; KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138
Product Details:
Place of Origin: China
Certification: ISO9001
Brand:YuanCheng
Payment & Shipping Terms:
Minimum Order Quantity:1kg
Supply Ability:500kg/month
Delivery Time:within 24 hours after payment
Payment Terms:Western Union, MoneyGram, T/T
Package:25kg/cardboad drum
Appearance:light yellow
Product Description:
CAS: 82640-04-8
M.F.: C28H28ClNO4S
M.W. :510.04
Purity:99.8%
M.P.: 250-253°C
M.S.:
EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds
The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S.HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.
EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.
Usage:
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk,
- Raloxifene hydrochloride